A single oral dose as part of an antiemetic regimen
VARUBI® (rolapitant) is administered approximately 1 to 2 hours before chemotherapy1
No dose adjustment of dexamethasone is required with VARUBI, as there are no drug interactions between VARUBI and dexamethasone.1
VARUBI is supplied as a single dose wallet card containing two 90-mg tablets.
- A single oral dose of VARUBI provides flexibility of administration; it may be given with either oral or intravenous (IV) 5-hydroxytryptamine-3 (serotonin) receptor antagonists (5-HT3 RAs) and dexamethasone1
- VARUBI can be administered with or without food1
- Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2-week intervals1
Combined antiemetic regimen dosing with VARUBI, a 5-HT3 RA, and dexamethasone1
For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy (HEC and MEC)
5-HT3, 5-hydroxytryptamine-3 (serotonin); HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; RA, receptor antagonist.
- VARUBI is an inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). Increased plasma concentrations of BCRP and P-gp substrates with a narrow therapeutic index may result in potential adverse reactions. Monitor for adverse reactions related to the concomitant drug if use with VARUBI cannot be avoided
- Avoid use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers (eg, rifampin) as significantly reduced plasma concentrations of VARUBI can decrease the efficacy of VARUBI